Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis board vacancy

Executive Summary

Aventis business development head and board member Thomas Hoefstatter announces plans to resign. He was expected to serve on the 18-member management committee of the newly merged company's board, and would have been one of 10 representatives of Aventis. Sanofi-Aventis says it is too soon to know how it will proceed with the management and board vacancy, but that it will meet its deadline for putting the new operational structure in place by Jan. 1 (1"The Pink Sheet" Aug. 2, 2004, p. 3)...

You may also be interested in...



Sanofi-Aventis Merger Clears FTC; Estorra Rights To Be Divested

Sanofi and Aventis will begin integrating management and operations following the Federal Trade Commission's July 28 approval of the merger of the two companies

DHS Guidance Smooths Potential Wrinkles In US Supplement Industry Being ‘Essential’ Nationwide

VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.

J&J Ramps Up Manufacturing Capacity To Produce 1 Billion Doses Of Candidate COVID-19 Vaccine

Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.

Topics

UsernamePublicRestriction

Register

PS044585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel